Chemours Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Chemours Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $6.64B | Feb 15, 2019 |
| FY2018 | Dec 31, 2017 | $6.18B | Feb 15, 2019 |
| FY2018 | Dec 31, 2016 | $5.40B | Feb 15, 2019 |
| FY2017 | Dec 31, 2015 | $5.72B | Feb 16, 2018 |
| FY2016 | Dec 31, 2014 | $6.43B | Feb 17, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.33B | Feb 24, 2026 |
| FY2025 | Sep 30, 2025 | $1.50B | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | $1.62B | Feb 24, 2026 |
| FY2025 | Mar 31, 2025 | $1.37B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.36B | Feb 24, 2026 |
| FY2025 | Sep 30, 2024 | $1.51B | Feb 24, 2026 |
| FY2025 | Jun 30, 2024 | $1.55B | Feb 24, 2026 |
| FY2025 | Mar 31, 2024 | $1.36B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.37B | Feb 18, 2025 |
| FY2024 | Sep 30, 2023 | $1.50B | Feb 18, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.58B | Feb 16, 2018 |
| FY2017 | Sep 30, 2017 | $1.58B | Feb 16, 2018 |
| FY2017 | Jun 30, 2017 | $1.59B | Feb 16, 2018 |
| FY2017 | Mar 31, 2017 | $1.44B | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $1.32B | Feb 16, 2018 |
| FY2017 | Sep 30, 2016 | $1.40B | Feb 16, 2018 |
| FY2017 | Jun 30, 2016 | $1.38B | Feb 16, 2018 |
| FY2017 | Mar 31, 2016 | $1.30B | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $1.36B | Feb 17, 2017 |
| FY2016 | Sep 30, 2015 | $1.49B | Feb 17, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $902.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $265.00M | Feb 24, 2026 |
| FY2024 | Sep 30, 2024 | $287.00M | Feb 18, 2025 |
| FY2024 | Jun 30, 2024 | $306.00M | Feb 18, 2025 |
| FY2024 | Mar 31, 2024 | $286.00M | Feb 18, 2025 |
| FY2025 | Dec 31, 2023 | $1.30B | Feb 24, 2026 |
| FY2024 | Sep 30, 2023 | $273.00M | Feb 18, 2025 |
| FY2024 | Jun 30, 2023 | $410.00M | Feb 18, 2025 |
| FY2024 | Mar 31, 2023 | $368.00M | Feb 18, 2025 |
| FY2024 | Dec 31, 2022 | $1.62B | Feb 18, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($47.00M) | Feb 24, 2026 |
| FY2025 | Sep 30, 2025 | $46.00M | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | ($380.00M) | Feb 24, 2026 |
| FY2025 | Mar 31, 2025 | ($5.00M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($11.00M) | Feb 24, 2026 |
| FY2025 | Sep 30, 2024 | ($32.00M) | Feb 24, 2026 |
| FY2025 | Jun 30, 2024 | $60.00M | Feb 24, 2026 |
| FY2025 | Mar 31, 2024 | $54.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($18.00M) | Feb 18, 2025 |
| FY2024 | Sep 30, 2023 | $12.00M | Feb 18, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $109.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $108.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $118.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $107.00M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $93.00M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $80.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $82.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $81.00M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $81.00M | Feb 15, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $799.00M | Feb 24, 2026 |
| FY2025 | Sep 30, 2025 | $122.00M | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | $424.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $598.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.29B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $710.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $592.00M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $527.00M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $548.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $657.00M | Feb 12, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $264.00M | Feb 24, 2026 |
| FY2025 | Sep 30, 2025 | $127.00M | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | ($19.00M) | Feb 24, 2026 |
| FY2025 | Mar 31, 2025 | ($112.00M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($633.00M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $556.00M | Feb 24, 2026 |
| FY2023 | Sep 30, 2023 | $74.00M | Mar 27, 2024 |
| FY2023 | Jun 30, 2023 | ($57.00M) | Mar 27, 2024 |
| FY2023 | Mar 31, 2023 | ($124.00M) | Mar 27, 2024 |
| FY2024 | Dec 31, 2022 | $755.00M | Feb 18, 2025 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $213.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $360.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $370.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $307.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $277.00M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $267.00M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $481.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $498.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $411.00M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $338.00M | Feb 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.38B | Feb 24, 2026 |
| FY2025 | Sep 30, 2025 | $7.55B | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | $7.46B | Feb 24, 2026 |
| FY2025 | Mar 31, 2025 | $7.38B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $7.51B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $8.24B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $7.64B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $7.55B | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $7.08B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $7.26B | Feb 11, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.13B | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | $7.23B | Feb 24, 2026 |
| FY2025 | Mar 31, 2025 | $6.81B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $6.94B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $7.52B | Feb 24, 2026 |
| FY2023 | Sep 30, 2023 | $7.20B | Mar 27, 2024 |
| FY2023 | Dec 31, 2022 | $6.53B | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $6.47B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $6.27B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $6.56B | Feb 12, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $250.00M | Feb 24, 2026 |
| FY2025 | Sep 30, 2025 | $274.00M | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | $228.00M | Feb 24, 2026 |
| FY2025 | Mar 31, 2025 | $566.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $571.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $721.00M | Feb 24, 2026 |
| FY2023 | Dec 31, 2022 | $1.11B | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.08B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $813.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $689.00M | Feb 12, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $46.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $102.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $102.00M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $102.00M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $153.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $153.00M | Feb 12, 2021 |
| FY2017 | Dec 31, 2017 | $153.00M | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $153.00M | Feb 16, 2018 |
| FY2017 | Dec 31, 2015 | $166.00M | Feb 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.22B | Feb 24, 2026 |
| FY2025 | Sep 30, 2025 | $1.28B | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | $1.25B | Feb 24, 2026 |
| FY2025 | Mar 31, 2025 | $1.64B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.69B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.78B | Feb 18, 2025 |
| FY2023 | Sep 30, 2023 | $1.84B | Mar 27, 2024 |
| FY2023 | Dec 31, 2022 | $2.17B | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.75B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $1.30B | Feb 11, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $670.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $713.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.20B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.10B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.45B | Mar 27, 2024 |
| FY2021 | Dec 31, 2020 | $1.11B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $943.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.20B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.56B | Feb 15, 2019 |
| FY2018 | Dec 31, 2016 | $902.00M | Feb 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $3.59B | Feb 17, 2017 |
| FY2016 | Dec 31, 2015 | $4.01B | Feb 17, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | (2) | Feb 24, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 18, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 18, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Jun 30, 2025 | (2) | Feb 24, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 18, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 18, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 149.89M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 149.43M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 148.59M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 148.50M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 161.05M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | 164.92M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | 163.57M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | 170.78M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | 182.96M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | 182.60M | Feb 16, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $148.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $149.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $154.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $164.00M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $164.00M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $164.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $148.00M | Feb 12, 2021 |